Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence
ESCHBORN, Germany, May 30, 2022 Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd.,...
Developing Innovative Therapeutics
Our Company
Inflection Biosciences is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory disease. The pipeline comprises of IBL-101, an oral, pan-PIM kinase inhibitor in development for autoimmune and inflammatory disease, IBL-202, selected from a series of unique dual mechanism kinase inhibitors and AUM302 (formerly IBL-302), partnered with AUM Biosciences.
